J Gynecol Oncol.  2024 Jan;35(1):e15. 10.3802/jgo.2024.35.e15.

Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment

Affiliations
  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan
  • 2Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan
  • 3Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
  • 4Department of Obstetrics and Gynecology, Kyorin University, Faculty of Medicine, Tokyo, Japan
  • 5Department of Obstetrics and Gynecology, Tokyo Women’s Medical University, Tokyo, Japan
  • 6Department of Obstetrics and Gynecology, Otaru General Hospital, Hokkaido, Japan
  • 7Department of Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
  • 8Department of Obstetrics and Gynecology, National Hospital Organization Sendai Medical Center, Sendai, Japan
  • 9Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyushu, Japan
  • 10Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
  • 11Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Shiwa, Japan
  • 12Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
  • 13Department of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan

Abstract

The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for cervical cancer, indicate appropriate current treatment methods for cervical cancer, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the economic and psychosomatic burden of patients by promoting the performance of appropriate treatment, and enhance mutual understanding between patients and healthcare professionals. The guidelines were prepared through the consensus of the JSGO Guideline Committee, based on a careful review of evidence gathered through the literature searches and the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise seven chapters and 5 algorithms. The main features of the 2022 revision are as follows: 1) added discussed points at the final consensus meeting; 2) revised the treatment methods based on the International Federation of Gynecology and Obstetrics 2018 staging system; 3) examined minimally invasive surgery based on Laparoscopic Approach to Cervical Cancer trial; 4) added clinical question (CQ) for treatments of rare histological types, gastric type, and small-cell neuroendocrine carcinoma; 5) added CQ for intensity-modulated radiation therapy; 6) added CQ for cancer genomic profiling test; and 7) added CQ for cancer survivorship. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2022 for the Treatment of Uterine Cervical Cancer.

Keyword

Clinical Practice Guideline; Uterine Cervical Neoplasms; Uterine Cervical Cancer; Guideline, Japan
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr